Affinity Asset Advisors’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Affinity Asset Advisors’s Portfolio KDNY Stock Details KDNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-321,017	Closed	-$12.3M	–	101
2023 Q2	$12.3M	Sell	321,017 -655,004	-67%	-$16.8M	4.31%	4
2023 Q1	$22.6M	Buy	976,021 +157,986	+19%	+$3.77M	7.46%	1
2022 Q4	$21.4M	Buy	818,035 +4,037	+0.5%	+$89.4K	8.41%	1
2022 Q3	$16M	Sell	813,998 -123,570	-13%	-$2.48M	4.47%	3
2022 Q2	$16.4M	Buy	937,568 +92,413	+11%	+$1.45M	6.91%	3
2022 Q1	$13.8M	Buy	845,155 +290,000	+52%	+$3.94M	2.21%	7
2021 Q4	$9.05M	Buy	555,155 +480,814	+647%	+$6.84M	3.29%	8
2021 Q3	$949K	Sell	74,341 -125,659	-63%	-$1.65M	0.24%	59
2021 Q2	$2.82M	Buy	200,000 +25,000	+14%	+$400K	1.01%	25
2021 Q1	$2.72M	Buy	175,000 +25,000	+17%	+$408K	0.92%	27
2020 Q4	$2.38M	Buy	+150,000	New	+$2.26M	1.26%	21

Affinity Asset Advisors's KDNY Position: Q3 2023 in Review

Affinity Asset Advisors sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q3 2023, closing a stake of 321,017 shares — an estimated $12.3M sold.

Affinity Asset Advisors first reported a position in KDNY in Q4 2020 and held it in 11 quarters. The position peaked at $22.6M in Q1 2023. 2 funds tracked by Wall St. Rank hold KDNY as of Q3 2023.

Affinity Asset Advisors reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Affinity Asset Advisors sold 321,017 Chinook Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $12.3M.
Affinity Asset Advisors first reported a position in Chinook Therapeutics, Inc. Common Stock in Q4 2020 and held it in 11 quarters.
Affinity Asset Advisors's Chinook Therapeutics, Inc. Common Stock position peaked at $22.6M in Q1 2023.
2 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Affinity Asset Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.